Memorial Sloan Kettering Cancer Center: Multiple Myeloma trials

The registry lists 76 Multiple Myeloma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 13 are open to participants now and 23 have results posted.

Early Phase 1 1Phase 1 22Phase 2 41Phase 3 3No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Elranatamab and Cyclophosphamide in People With Multiple MyelomaRecruitingNCT07454382Phase 2
• A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell TherapyRecruitingNCT07249528
• A Dietary Study for People With Multiple MyelomaRecruitingNCT07226609Not applicable
• A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingNCT07105059Phase 1
• A Study of Dara-RVd and Teclistamab-RVd in People With Multiple MyelomaRecruitingNCT07099391Phase 1/2
• Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaRecruitingNCT06976476Phase 2
• A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantRecruitingNCT06679829Phase 2
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
• A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell TherapyRecruitingNCT06066346Phase 2
• A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)RecruitingNCT06055894Not applicable
• In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PETRecruitingNCT05093335Early Phase 1
• Study of CAR-T Therapy in Older PatientsRecruitingNCT04300998
• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruitingNCT00582621
• Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaTerminatedNCT04635735Phase 1/2Results posted
• Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerCompletedNCT04478123Phase 2Results posted
• Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or LymphomaActive, not recruitingNCT04459416Phase 3Results posted
• A Study of Colesevelam for Lenalidomide-Associated DiarrheaCompletedNCT03767257Phase 2Results posted
• First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal AntibodyCompletedNCT03665155Phase 1/2Results posted
• Short Course Daratumumab in Patients With Multiple MyelomaCompletedNCT03490344Phase 2Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• High Dose Carfilzomib for Newly Diagnosed MyelomaCompletedNCT02937571Phase 1/2Results posted
• CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationCompletedNCT01995708Phase 1Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaCompletedNCT01866293Phase 1/2Results posted
• Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedNCT01755975Phase 1/2Results posted
• Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple MyelomaCompletedNCT01745588Phase 2Results posted
• Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide MaintenanceCompletedNCT01463670Phase 2Results posted
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisCompletedNCT01383759Not applicableResults posted
• Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01351623Phase 2Results posted
• Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte InfusionsCompletedNCT01131169Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance LCompletedNCT00807599Phase 2Results posted
• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell DisordersActive, not recruitingNCT06126341
• A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisActive, not recruitingNCT05775094Phase 1
• A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
• A Study of MCARH109 and MCARH125 in People With Multiple MyelomaActive, not recruitingNCT05431608Phase 1
• A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantActive, not recruitingNCT05393804Phase 2
• Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingNCT05354557Phase 2
• A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple MyelomaCompletedNCT05139225Phase 1
• Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingNCT05130827Phase 2
• MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple MyelomaActive, not recruitingNCT04555551Phase 1
• A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomideActive, not recruitingNCT04497961Phase 2
• A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With MyelomaWithdrawnNCT04467281Phase 2
• Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative RemissionActive, not recruitingNCT04221178
• A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
• A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
• Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell TransplantationCompletedNCT03508765Not applicable
• Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisActive, not recruitingNCT03315026Phase 2
• Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell TransplantationCompletedNCT03276481
• BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple MyelomaCompletedNCT03070327Phase 1
• Mobile Health Device Study for Myeloma PatientsCompletedNCT03006315
• Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.Active, not recruitingNCT02909036Phase 1
• A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedNCT02831686Phase 1
• Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyCompletedNCT02697383Phase 1
• Lenalidomide Maintenance in Plasma Cell MyelomaActive, not recruitingNCT02538198Phase 2
• Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation PatientsCompletedNCT01811862Not applicable
• Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
• Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
• Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell TransplantCompletedNCT01416246Not applicable
• Behavioral Intervention For BMT/SCT SurvivorsCompletedNCT00579917
• Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisCompletedNCT00089167Phase 2
• Pyroxamide in Treating Patients With Advanced CancerCompletedNCT00042900Phase 1
• Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell TransplantationCompletedNCT00014482Not applicable
• Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple MyelomaCompletedNCT00008268Phase 2
• Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple MyelomaCompletedNCT00008242Phase 2
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
• St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00005634Phase 1
• Arsenic Trioxide in Treating Patients With Advanced Hematologic CancerCompletedNCT00003395Phase 1
• Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
• Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeCompletedNCT00002502Phase 2